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It was reported that induced pluripotent stem (iPS) cells went through mesenchymal-epithelial transition (MET) 
when they were generated from embryonic fibroblasts by introduction of reprogramming genes. The results 
prompted us to study whether cancer cells under epithelial-mesenchymal transition (EMT) could be reversed by 
the reprogramming genes. To this end, we used fibroblast-like squamous cell cancer (SCC) lines derived from 
mouse skin, and the piggyBac transposon system to deliver the reprogramming factors (Oct3/4, Sox2, Klf4, 
c-Myc and Lin28), which were linked by self-cleaving peptides. The piggyBac transposon and piggyBac 
transposase expression vector were co-transfected into spindle-shaped SCC cells. The stable transformants were 
obtained after the puromycin selection, and they showed polygonal morphology with well-established cell-cell 
adhesion. Quantitative RT-PCR and immunoblotting revealed increased epithelial markers and reduced 
mesenchymal markers in the transformed cells compared with the parental SCC cells. Also, the transformed cells 
showed N-cadherin at the cell-cell border and actin bundles, similar to those found in epithelial cells. Cell 
proliferation and cell invasion activity were reduced in the transfected cells. The EMT in human SCC cells also 
showed a reversal with the reprogramming genes. Taken collectively, these results suggested that a malignant 
process associated with EMT was reversed by introduction of the reprogramming genes for iPS cells. This 
finding provides an idea for the potential therapeutic use of the reprogramming genes to attenuate malignant 
nature of metastatic cancer. 
